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and for the DELTA groupAbstract
Background: Central to the design of a randomised controlled trial is the calculation of the number of participants
needed. This is typically achieved by specifying a target difference and calculating the corresponding sample
size, which provides reassurance that the trial will have the required statistical power (at the planned statistical
significance level) to identify whether a difference of a particular magnitude exists. Beyond pure statistical or scientific
concerns, it is ethically imperative that an appropriate number of participants should be recruited. Despite the critical
role of the target difference for the primary outcome in the design of randomised controlled trials, its determination
has received surprisingly little attention. This article provides guidance on the specification of the target difference
for the primary outcome in a sample size calculation for a two parallel group randomised controlled trial with a
superiority question.
Methods: This work was part of the DELTA (Difference ELicitation in TriAls) project. Draft guidance was developed by
the project steering and advisory groups utilising the results of the systematic review and surveys. Findings were
circulated and presented to members of the combined group at a face-to-face meeting, along with a proposed
outline of the guidance document structure, containing recommendations and reporting items for a trial protocol and
report. The guidance and was subsequently drafted and circulated for further comment before finalisation.
Results: Guidance on specification of a target difference in the primary outcome for a two group parallel randomised
controlled trial was produced. Additionally, a list of reporting items for protocols and trial reports was generated.
Conclusions: Specification of the target difference for the primary outcome is a key component of a randomized
controlled trial sample size calculation. There is a need for better justification of the target difference and reporting of
its specification.
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Well-conducted randomised controlled trials (RCTs) are
widely viewed as providing the optimal evidence on the
relative performance of competing healthcare interven-
tions [1,2]. However, simply detecting any statistical dif-
ference in the effectiveness of interventions may not be
sufficient or useful; if the interventions differ to a degree
or in a manner that is of little consequence in patient,
clinical or economic (or other meaningful) terms, then the
interventions might be considered not to be different. If
RCTs are to produce useful information that can help pa-
tients, clinicians and planners make decisions about health
care, it is essential that they are designed to achieve this.
This is typically achieved by specifying a target difference
for a primary outcome as part of a sample size calculation,
which provides reassurance that the trial will have the spe-
cified statistical power to identify whether a difference of a
particular magnitude exists. Beyond purely statistical or
scientific concerns, the sample size calculation has finan-
cial and ethical implications. Failing to recruit sufficient
participants to be able to confidently detect a relevant dif-
ference between interventions may be viewed as an ineffi-
cient use of finite research resources, while recruiting
substantially more than are needed risks exposing partici-
pants to unnecessary experimentation [3].
Given these considerations, determining an appropriate
sample size is of critical importance. Surprisingly, little
practical advice is available on specifying the target differ-
ence of the chosen primary outcome, which as noted
above is a key component of the sample size calculation.
A comprehensive systematic review of the literature iden-
tified methods for determining the target difference that
are available and surveys have shown these methods are in
use [4,5]. Nevertheless, uncertainty regarding the magni-
tude of the target difference when designing the trial will
lead to uncertainty regarding the interpretation of the re-
sults, even when the trial is otherwise successfully con-
ducted [6,7].
This article aims to provide practical guidance primarily
for researchers involved in determining the sample size
for an RCT and, in particular, the specification of the tar-
get difference in the primary outcome. It is also relevant
to those who are involved in commissioning and publish-
ing such studies. We provide guidance on the choice of
the primary outcome, specification of the target difference
and a brief summary of available methods that can be used
to inform its specification and reporting. Additionally, two
sets of reporting items, one for a trial protocol and the
other a report of the trial findings in a peer reviewed bio-
medical journal, are also proposed and examples provided.
A comprehensive systematic review and discussion of the
individual methods for specifying a target difference has
been reported elsewhere [4,5]. The focus of this guidance
is upon what might be termed the conventional, orstandard, approach to an RCT sample size calculation: a
standalone trial utilising the conventional statistical frame-
work for sample size calculation and primarily for super-
iority trials (those where the difference to be detected is
specified). The key issues considered are relevant to other
RCT designs and analysis approaches though implementa-
tion may differ. We note that the conventional approach
to sample size calculation is not without its limitations and
alternatives have been proposed [8], nevertheless it con-
tinues to be the most widely adopted approach [1,9].
The conventional approach to the sample size calcula-
tion for a two parallel group RCT is as follows:
1. The RCT is conceived as a standalone definitive
study (a study that is designed to provide a
meaningful answer on its own);
2. It addresses a superiority question evaluating
evidence of a difference (in either direction);
3. Adoption of a two parallel-group RCT design (typically
1:1 allocation);
4. Application of the Neyman-Pearson framework to
calculate the sample size [2,10-12]. This requires
specification of: the primary outcome for which the
required sample size is to be calculated; the target
difference (specification varies according to outcome
type); statistical parameters (significance level and
power) and other component(s) of the sample size
calculation (such as standard deviation (SD)).
Methods
Development of the guidance
This work was part of the DELTA (Difference ELicitation
in TriAls) project, a study on target differences commis-
sioned by the Medical Research Council/National Institute
for Health Research Methodology Research Panel (MRC/
NIHR) in the United Kingdom. It comprised three inter-
linking components: a comprehensive systematic review
of methods for specifying the target difference, two sur-
veys of current practice amongst clinical trialists and gen-
eration of structured guidance. This article is an abridged
version of this guidance and other components of the
project which have been reported in full elsewhere [4].
DELTA was undertaken by a collaborative group in which
the majority of members have extensive experience of the
design and conduct of RCTs (both as investigators and as
independent committee members) and have conducted
methodological research related to RCTs (such as quality-
of-life measurement, statistical methodology, reporting,
surgical trials and economic evaluation). The draft guid-
ance was developed by the project steering and advisory
groups utilising the results of the systematic review and
surveys. Findings were circulated and presented to mem-
bers of the combined group at a face-to-face meeting,
along with a proposed outline of the guidance document
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items for a trial protocol and report. Both the structure
and main recommendations were agreed at this meeting.
The guidance was subsequently drafted and circulated for
further comment before finalisation. No ethical approval
was needed for this research.
Scope of the guidance
This guidance is based upon the conventional approach to
a sample size calculation, though it should be applicable to
most RCTs [1,9]. However, other approaches, for example
trials with an explicitly Bayesian analysis framework, will
require adaptation of the reporting items. It focuses upon
guidance for a trial with a ‘superiority’ question; one which
seeks evidence of a difference between intervention groups.
Although this guidance is primarily aimed at researchers, it
is also relevant for publishers, funders and commissioners
of research.
Results
Abridged guidance is given below.
Choosing the primary outcome
In the conventional approach to the sample size calcula-
tion for an RCT, a single outcome is usually chosen to
be the primary measure upon which the sample size cal-
culation is based (in some cases more than one primary
outcome may be appropriate) [2,10,13]. The specification
of a primary outcome performs a number of functions in
terms of trial design, but it is clearly a pragmatic simplifi-
cation to aid the design, interpretation and use of RCT
findings. Through the corresponding sample size calcula-
tion and specification of the target difference, it clarifies
what the study aims to identify, and the statistical power
and precision with which this can be achieved. Stating
the primary outcome in the study protocol also helps
prevents undue over-interpretation arising from testing
multiple outcomes and selective outcome reporting bias,
whereby authors report only statistically significant (on
possibly clinically irrelevant) outcomes or change the pri-
mary focus of the study to match a statistically significance
finding. Additionally, it helps clarify the initial basis upon
which to judge the study findings. This is particularly im-
portant in presence of a ‘negative’ result, where the result
does not meet the criteria for statistical significance (typic-
ally 5%). In all cases, focus should be upon the confidence
interval as well as the point estimate, where a justifiable
target difference can guide the interpretation. However,
such justification of the target difference is often lacking
in trial reports [1,6]. Calculating (or reverse engineering)
the magnitude of a difference that can be detected at con-
ventional levels of statistical significance and power (typic-
ally two-sided 5% and 80%, respectively), given a sample
size which is believed to feasible, is often performed inpractice for a selection of key outcomes before determin-
ing the primary outcome. Nevertheless, it is important to
report the final sample size calculation, including the
chosen primary outcome, the target difference and any
justification of the value chosen, in as robust and transpar-
ent a fashion as possible to allow others to judge the basis
of the calculation.
Specifying the target difference
The specification of the target difference in an RCT sam-
ple size calculation has received surprisingly little discus-
sion in the literature. For a superiority trial, it is the
difference in the primary outcome value that the study is
designed to detect reliably [2,10,13]. There are two main
bases for specifying the target difference: a difference con-
sidered to be ‘important’ (for example, by a stakeholder
group such as health professionals or patients), and a ‘real-
istic difference’ based upon current evidence (for example,
seeking the best available estimates in the literature through
some form of knowledge synthesis).
It has been argued that a target difference should al-
ways meet both of these criteria [14]. The desire to be
able to consider an (clinically) important difference can
be viewed as a middle ground between ignoring the con-
sequences of the treatment decision and a full assess-
ment of the benefits, harms and costs of an intervention
against the alternatives, which seeks to ensure that any
harms and costs are incurred for a good reason. Focus-
ing on a benefit (or harm) of the most important out-
come is a natural and intuitive, if imperfect, way to
guide a decision. A large body of literature exists on de-
fining a clinically important difference, though not in the
context of an RCT sample size calculation [15-17]. The
most common general approach is the minimal clinically
important difference (MCID). This has been defined as
‘the smallest difference …. which patients perceive as
beneficial and which would mandate, in the absence of
troublesome side effects and excessive cost, a change in
the patient’s management’, or more simply as ‘minimum
difference that is important to a patient’ [17]. Many vari-
ants on this basic approach exist [18,19]. In the context of
specifying a target difference for a typical two parallel-
group trial, the focus is on a difference at the group level,
between two groups of different participants. This con-
trasts with the vast majority of the MCID (and related)
literature, which focuses overwhelmingly upon within-
patient change and whether an important difference
can be said to have occurred [15-17]. An alternative
approach is to consider all relevant issues, including
the consequences of decision-making, whereby a differ-
ence of any magnitude can be viewed as important and
therefore a study’s size (and implicitly the target differ-
ence) is determined by reference to resource implications
[20,21]. Whatever definition is used, estimation of an
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itations [22,23].
The other main basis for a target difference is to specify
a realistic difference; there is, for example, little point in
setting as the target difference one that is so large that it
cannot plausibly exist. If a systematic review of RCTs on
the research question is available, it can be used to specify
what difference is supported by current evidence. In es-
sence, a realistic difference makes no claim regarding its
clinical importance or otherwise. However, where a realis-
tic difference is used, consideration of the importance of
the difference is needed if the study findings are intended
to inform clinical, patient or policy decisions. For some
outcomes, the importance may be very clear (for example,
mortality), whereas for others (especially quality of life
and surrogate outcomes) further explanation is needed.
Recruitment, study management and finance will nat-
urally come into play when determining the sample
size of a study. However, such considerations do not neg-
ate concerns about what is a realistic and/or important
difference.Table 1 Methods for specifying an important and/or realistic
Name Description
Anchor The outcome of interest can be ‘anchored’ by using either a
important difference. This may be achieved by comparing a
linking this change to participants who showed improvemen
which either patients or health professionals more readily ag
difference). An outcome can be anchored to another which
as individuals with varying severity of a disease) can also be
Distribution Approaches that determine a value based upon distribut
that is larger than the inherent imprecision in the measu
level for a noticeable difference.
Health economic Approaches that use principles of economic evaluation. Th
outcomes, and define a threshold value for the cost of a un
to estimate the overall net benefit of treatment. The net be
the form of a (typically Bayesian) decision-theoretic value o
a value of information analysis simpler heuristic frameworks
have been proposed.
Opinion-seeking The target difference can be based on opinions elicited f
approaches include forming a panel of experts, surveying
interviewing individuals. This elicitation process can be ex
Pilot study A pilot (or preliminary) study may be carried out where the
expectations and determine an appropriate target differenc
could be used to inform a phase three study, though this w
differences (such as inclusion criteria and outcomes), which
Review of
evidence base
The target difference can be derived using current eviden
from a systematic review or meta-analysis of RCTs. In the
observational studies could be used in a similar manner.
studies in which an important difference was determined
Standardised
effect size
The magnitude of the effect on a standardised scale defi
outcome, the standardised difference (most commonly e
Cohen’s cutoff values of 0.2, 0.5 and 0.8 for small, medium
medium effect corresponds simply to a change in the ou
outcome metrics (such as an odds, risk or hazard ratio) ca
recognised cutoff values exist. Cohen’s cutoff values appr
Corresponding risk ratio values vary according to the conFor a superiority trial it is generally accepted that the
target difference should be a clinically important differ-
ence [2,10-12] or ‘at least as large as the MCID [minimum
clinically important difference]’ [24]. The target difference
in a conventional sample size calculation is not the mini-
mum difference that can be statistically detected; statis-
tical significance alone is not a sufficient consideration for
attributing importance to a difference [2,12].
The target difference is specified differently depending
upon the type of primary outcome. For a continuous out-
come, this target difference on either the original or
standardised scale is often referred to as the ‘effect size’.
Strictly speaking, this value alone does not fully (uniquely)
specify the target difference; the assumed variability of the
outcome (standard deviation) is also needed to convert
the effect size between the original and standardised
scales. For a binary outcome, the target difference will be
conditional on the control group event proportion. To
uniquely specify the sample size, the target difference and
the control group event proportion are needed, which to-
gether imply a unique pair of absolute and relative targetdifference [5]
Difference
specified
patient’s or health professional’s judgement to define an
patient’s health before and after treatment, and then
t and/or deterioration using a more familiar outcome (for
ree on what amount of change constitutes an important
more is known about. Contrasts between patients (such
used to determine a meaningful difference.
Important
ional variation. A common approach is to use a value
rement and therefore likely to represent a minimal
Important
ese typically include both resource cost and health
it of health effect that a decision-maker is willing to pay,
nefit can be analysed in a frequentist framework or take
f information analysis. Due to difficulties in implementing
, also based on the principles of economic evaluation,
Important
rom health professionals, patients or others. Possible
the membership of a professional or patient body or
plicitly framed within a trial context.
Important
and/or realistic
re is little evidence, or even experience, to guide
e for the trial. In a similar manner, a phase two study
ould need to take account of methodological
should be reflected in the target difference.
Realistic
ce on the research question. Ideally, this would be
absence of randomised evidence, evidence from




nes the value of the difference. For a continuous
xpressed as Cohen’s d effect size) can be used.
and large effects, respectively, are often used. Thus a
tcome of 0.5 SDs. Binary or survival (time-to-event)
n be utilised in a similar manner, though no widely
oximate odds ratios of 1.44, 2.48 and 4.27, respectively.
trol group event proportion.
Important
Table 2 Reporting items for the protocol and report of a two parallel group superiority trial
Item no. Item description Protocol Report
1 State any divergence from the conventional approach. √ √
2 State the primary outcome (and any other outcome which the study sample size calculation is based upon),
or state why there is not one.
√ √
3 Reference the formula and/or simulation approach if the standard binary, continuous or survival outcome
formulas are not used [2,11]. The primary analysis should be stated in the statistical analysis section.
√
4 State the values used for statistical parameters (such as significance level and power). √ √
5 State the underlying basis for determining the target difference: √
a. an important difference as judged by a stakeholder,
b. a realistic difference based upon current knowledge or
c. both an important and realistic difference.
6 Express the target difference according to the outcome type: √ √
a. Binary: state the target difference as an absolute and/or relative effect, along with the intervention and control
group proportions. If both an absolute and a relative difference are provided, clarify if either takes primacy in terms
of the sample size calculation.
b. Continuous: state the target mean difference on the natural scale, the common SD and standardised effect size
(mean difference/SD). It is preferable to also provide the anticipated control group mean even though it is not
required for the sample size calculation.
c. Time-to-event (survival): state the target difference as an absolute and/or relative difference, provide the control
group event proportion, along with the intervention and control group survival distributions. Additionally, the
planned length of follow-up should be stated along with the assumed accrual pattern. If both an absolute and a
relative difference are provided, clarify if either takes primacy in terms of the sample size calculation.
7 Explain the choice of target difference: specify and reference any formal method used or relevant previous research. √
8 State the sample size based upon the assumptions specified above (for a time-to-event outcome, the number of
events required should also be stated). If any factors are incorporated which alter the required sample size (such as
allowance for loss-to-follow-up) they should also be specified along with the final sample size.
√ √
9 Reference the trial protocol √
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trol group proportion or survival distribution and length
of follow-up period to be stated, in addition to the target
difference. This is necessary as the sample size required is
sensitive to both the absolute level and the relative differ-
ence. Despite this, it is not uncommon for only one or the
other to be specifically stated in trial reports.Table 3 Reworked example RCT protocol sample size calculat
Primary outcome type Example text
Binary Men After Prostate Surgery (MAPS) radical prostatec
was based upon a target difference of 15% absolute
determined as both a realistic and important differe
group, and inspection of the proportion of urinary i
The control group proportion is also based upon th
significance to the two-sided 5% level and seeking
Continuous Full-thickness macular hole and Internal Limiting Mem
Treatment Diabetic Retinopathy Study) distance visua
common standard deviation (SD) of 12, was assumed
as an important difference by patients and clinicians.
observational comparative study [30,31]. This target d
statistical significance to the two-sided 5% level and s
Time to event Arterial Revascularisation Trial (ART) [32]: The primar
difference of 5% in 10-year mortality with a control
proportions are realistic based upon a systematic re
to the two-sided 5% level and seeking 90% power,
total. Participants will be followed for 10 years.Seven methods for specifying the target difference have
been identified [4] which can be used to inform the choice
of target difference: anchor, distribution, health eco-
nomic, opinion-seeking, pilot study, review of the evi-
dence base and standardised effect size (see Table 1 for a
brief summary and elsewhere for a summary of the litera-
ture assessment of the use of each method [5]).ion sections
tomy trial [28]: The primary outcome is continence. The sample size
difference (85 versus 70%). This magnitude of a target difference was
nce from discussion between clinicians and the project management
ncontinence in the trials included in the Cochrane systematic review [29].
e observed proportion in the RCTs in this review. Setting the statistical
90% power, 174 participants per group are required; 348 in total.
brane peeling Study (FILMS) [7]: The primary outcome is ETDRS (Early
l acuity. A target difference of a mean difference of five letters, with a
as five letters is equivalent to one line on a visual acuity chart and is viewed
The SD value was based upon two previous studies; one RCT and one
ifference is equivalent to a standardised effect size of 0.42. Setting the
eeking 90% power, 123 participants per group are required; 246 in total.
y outcome is all-cause mortality. The sample size was based upon a target
group mortality of 25%. Both the difference and control group mortality
view of observational (cohort) studies [33]. Setting the statistical significance
1464 participants per group are required; 2,928 participants (651 events) in
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difference
The assumptions made in the sample size calculation
should be clearly specified. All inputs should be clearly
stated so that the calculation can be replicated. It is rec-
ommended that trial protocols clearly and fully state the
sample size calculations, including where the approach
taken differs from the conventional approach (for ex-
ample, the adoption of a Bayesian framework instead of a
frequentist approach), statistical parameters and the target
difference, with justification for the choice of values. Due
to space restrictions in many publications the main trial
paper is likely to contain less detail. A minimum set of
items for the main trial results paper along with full speci-
fication in the trial protocol is recommended below in
Table 2. These are more extensive lists of reporting items
building upon the Consolidated Standards for Reporting
Trials (CONSORT) including the 2010 version) and Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) statements, which provide guidance on reporting
the sample size calculation, but not explicitly how to re-
port the target difference and its justification [25-27]
Examples for the three most common outcome types are
provided in Table 3.
Discussion
The RCT is widely considered to be the best method for
comparing the effectiveness of health interventions [1].
Determining the target difference is a key element of an
RCT design. Improved standards in both RCT sample
size calculations and reporting of these calculations
would aid health professionals, patients, researchers and
funders in judging the strength of the available evidence
and would ensure better use of scarce resources. While
no single method provides a perfect solution to a diffi-
cult question, we have provided practical guidance for
researchers on sample size calculation with reference to
specifying the target difference and how this should be
reported in trial protocols and reports. To our know-
ledge, no alternative guidance exists. Although our ex-
amples and framing are from a medical context, the
issues are relevant to social care, animal and other non-
medical research as well. Further research into the im-
plementation, practicality and consequence of using
alternative methods for specifying the target difference
(such as health economic and opinion-seeking), and ex-
ploration of the justification of some methods (such as
the standardised effect size method, where the magni-
tude of the effect is used to infer the important of a
difference) is needed.
Conclusions
Specification of the target difference for the primary out-
come is a key component of an RCTsample size calculation.There is a need for better justification of the target differ-
ence and for corresponding reporting of its specification.
Raising the standard of RCT sample size calculations
would aid health professionals, patients, researchers and
funders in judging the strength of the evidence and would
ensure better use of scarce resources.Abbreviations
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